TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN), a leading predictive drug discovery company, today announced
that Anat Cohen-Dayag, PhD, President and Chief Executive Officer,
Compugen, will present aspects of the Company’s immune checkpoint
programs at two oncology conferences in Boston this month.
Dr. Cohen-Dayag will deliver a presentation at the Jefferies
Immuno-Oncology Summit, to be held on April 15, 2015. In her talk, Dr.
Cohen-Dayag will discuss Compugen’s broadly applicable predictive
discovery approach with emphasis on its first focused discovery program,
which resulted in the identification of multiple novel immune checkpoint
candidates. Dr. Cohen-Dayag will also present experimental data for
selected Compugen-discovered novel immune checkpoints now being advanced
by the Company as target candidates for cancer immunotherapy.
In addition, Dr. Cohen-Dayag will participate in a panel discussion
titled Focus on Immunotherapy: The Future at the Cancer
Advance Boston conference at Harvard Medical School, Harvard
University on April 14, 2015.
About Compugen’s Programs for Cancer Immunotherapy
Compugen’s cancer immunotherapy programs are based on eleven novel
B7/CD28-like immune checkpoint candidates and four novel
immunomodulators distinct from the B7/CD28-like proteins, all of which
were initially predicted in silico by Compugen. Immune
checkpoints, including inhibitory receptors and ligands, are
immunomodulatory proteins which are crucial for the maintenance of
self-tolerance (the prevention of autoimmunity) and for the protection
of tissues from damage during an immune response. Immune checkpoints are
"hijacked" by tumors to block the ability of the immune system to
destroy the tumor cells. Therapeutic blockade of immune checkpoints can
boost anti-tumor immunity, enabling the patient’s immune system to
recognize and attack the tumor cells, and mount durable anti-tumor
responses leading to tumor destruction.
About Compugen
Compugen is a leading predictive drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The Company
utilizes a broad and continuously growing integrated infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational biology
capabilities for the in silico (by computer) prediction and
selection of novel drug target candidates, which are then advanced in
its Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected Compugen-discovered
novel target candidates is performed by Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. For
additional information, please visit Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of terminology such as “will,”
“may,” “expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Some of these risks
include: that Compugen’s business model is substantially dependent on
entering into collaboration agreements with third parties and may not be
successful in generating revenues, and that the development and
commercialization of therapeutic products includes many inherent risks,
including failure to receive regulatory approval. These and other
factors are more fully discussed in the "Risk Factors" section of
Compugen’s most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission as well as other documents that may
be subsequently filed by Compugen from time to time with the Securities
and Exchange Commission. In addition, any forward-looking statements
represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent
date. Compugen does not assume any obligation to update any
forward-looking statements unless required by law.